VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
GRAL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
GRALGRAIL Inc.
$132.55$5.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGRALBalance Sheet

GRAIL Inc. (GRAL) Balance Sheet

8Y historyFree accessUpdated daily

Total assets have shrunk to $2.8B from $4.7B in 2024Q1, with cash down to $55.6M, while goodwill of $1.8B (64% of assets) poses impairment risk that could erode the $2.5B equity.

Income StatementBalance SheetCash FlowRatios

GRAL Balance Sheet

Annual statement

GRAL Balance Sheet

GRAIL Inc. (GRAL) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets914.72M953.85M819.86M156.06M295.63M242.73M595.92M557.51M649.23M
Cash & Short-Term Investments861.61M904.43M763.47M97.29M241.6M221.16M583.48M544.34M641.35M
Cash Only55.65M249.73M214.23M97.29M241.6M221.16M170.19M143.19M95.09M
Short-Term Investments805.96M654.7M549.24M000413.29M401.15M546.26M
Accounts Receivable19.76M18.3M24.64M22.35M18.61M6.88M000
Days Sales Outstanding41.2745.3771.6187.63122.31171.91---
Inventory17.76M16.02M18.63M21.7M19.75M0000
Days Inventory Outstanding34.5627.8733.441.9641.92----
Other Current Assets015.11M0006.89M000
Total Non-Current Assets1.93B1.97B2.16B4.4B5.31B9.5B110.38M78.01M37.61M
Property, Plant & Equipment133.25M103.88M135.43M169.38M198.72M216.37M101.39M59.46M33.04M
Fixed Asset Turnover1.48x1.42x0.93x0.55x0.28x0.07x---
Goodwill000888.94M1.5B6.2B000
Intangible Assets1.78B1.85B2.02B2.69B2.94B3.07B000
Long-Term Investments06.97M04.22M4.53M02.05M15.16M1.63M
Other Non-Current Assets14.32M6.75M11.12M7.98M6.14M7.1M6.94M3.38M2.94M
Total Assets2.84B2.92B2.98B4.56B5.6B9.74B706.3M635.52M686.85M
Asset Turnover0.06x0.05x0.04x0.02x0.01x0.00x---
Asset Growth %-14.96%-2.05%-34.53%-18.66%-42.47%1278.73%11.14%-7.47%-
Total Current Liabilities83.54M79.67M76.92M163.61M134.94M97.89M83.97M44.93M74.16M
Accounts Payable7.24M2.08M4.84M19.67M17.48M17.65M24.51M6.09M12.75M
Days Payables Outstanding8.673.628.6838.0537.156.2---
Short-Term Debt011.71M014.81M13.34M0000
Deferred Revenue (Current)001.6M000000
Other Current Liabilities1.11M65.87M22.69M87.64M65.96M4.51M12.41M23K267K
Current Ratio10.95x11.97x10.66x0.95x2.19x2.48x7.10x12.41x8.75x
Quick Ratio10.74x11.77x10.42x0.82x2.04x2.48x7.10x12.41x8.75x
Cash Conversion Cycle67.1669.6296.3391.54127.14----
Total Non-Current Liabilities217.49M264.48M402.98M747.13M821M209.51M60.49M40.06M12.32M
Long-Term Debt043.15M0000000
Capital Lease Obligations168.33M43.15M54.88M69.6M82.67M96.75M57.54M36.64M800K
Deferred Tax Liabilities772.59M218.58M345.86M676.03M735.19M0000
Other Non-Current Liabilities3.17M-40.4M2.24M1.5M3.13M112.76M2.95M3.42M11.52M
Total Liabilities301.03M344.15M479.9M910.74M955.94M307.4M144.46M84.99M86.47M
Total Debt91.31M98.01M68.14M84.41M96.01M110.56M62.99M42.04M2.52M
Net Debt35.66M-151.72M-146.09M-12.88M-145.59M-110.6M-107.21M-101.15M-92.57M
Debt / Equity0.04x0.04x0.03x0.02x0.02x0.01x0.11x0.08x0.00x
Debt / EBITDA-0.21x--------
Net Debt / EBITDA-0.08x--------
Interest Coverage---------
Total Equity2.54B2.58B2.5B3.65B4.65B9.43B561.84M550.53M600.37M
Equity Growth %2.99%2.97%-31.34%-21.52%-50.73%1578.52%2.05%-8.3%-
Book Value per Share58.9870.1478.47117.42149.62303.694.544.475.26
Total Shareholders' Equity2.54B2.58B2.5B3.65B4.65B9.43B561.84M550.53M600.37M
Common Stock45K40K34K11.42B10.96B10.34B151K138K129K
Retained Earnings-10.42B-10.21B-9.8B-7.78B-6.31B-911.54M-1.62B-1.31B-1.06B
Treasury Stock000000000
Accumulated OCI1.84M2.65M1.45M1.07M894K315K3.6M2.46M128K
Minority Interest000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Reimbursement and cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Shrinks as Cash Burns

Total assets declined from $4.7B in 2024Q1 to $2.8B in 2026Q2, per reported figures, as cash fell from $974.1M to $55.6M, indicating a rapid depletion of the post-spin-off cushion.

The balance sheet is contracting as the company consumes its cash reserves to fund operations and clinical trials. The decline in total assets is driven primarily by cash burn, with cash dropping from $974.1M in 2024Q1 to $55.6M in 2026Q2, a 94% reduction. This trajectory suggests that without additional capital raises or a path to profitability, the company's liquidity buffer is eroding, though the low debt levels provide some flexibility.

Minimal Leverage Masks Refinancing Risk

Debt-to-equity remains low at 0.04 in 2026Q2, per balance sheet data, with total debt of $91.3M, but the company's negative operating margins and cash burn suggest that any future borrowing could be costly.

The company's leverage is minimal, with a D/E ratio of 0.04 and total debt of $91.3M, which is modest relative to equity of $2.5B. However, the lack of significant debt may indicate limited access to credit markets given the company's negative profitability and cash burn. The low leverage provides a cushion, but investors should monitor whether the company can secure favorable financing terms if needed to extend its runway.

Goodwill Dominates Asset Base

Goodwill of $1.8B represents 64% of total assets in 2026Q2, per balance sheet data, while PPE is only $133.3M, indicating an asset-light model with significant intangible risk.

The asset mix is heavily weighted toward goodwill and intangibles, which totaled $1.8B in 2026Q2, down from $2.1B in 2024Q3, suggesting potential impairment charges. PPE is modest at $133.3M, reflecting a laboratory-based model with low capital intensity. The concentration in goodwill raises the risk of future write-downs if the company's market value or growth prospects deteriorate, which could further erode equity.

Accumulated Deficit Deepens

Retained earnings worsened to -$10.4B in 2026Q2, per balance sheet data, reflecting cumulative losses of over $2.4B since the spin-off, while equity remains positive at $2.5B due to the large goodwill balance.

The equity position is supported by the large goodwill balance, but the accumulated deficit of -$10.4B highlights the magnitude of losses incurred. The company has not repurchased shares or paid dividends, and stock-based compensation of $19.6M in 2026Q2, per cash flow data, adds to dilution. The equity quality is questionable as it relies on intangible assets that may be subject to impairment, and the ongoing losses suggest that equity could be at risk if impairments occur.

Liquidity Cushion Narrows Rapidly

Current ratio remains high at 10.95 in 2026Q2, per balance sheet data, but cash of $55.6M covers only a fraction of quarterly operating losses, which averaged -$80M in free cash flow.

The current ratio of 10.95 suggests strong short-term liquidity, but this is misleading as the company's cash balance of $55.6M is insufficient to cover even one quarter of operating losses, which were -$173.8M in 2026Q2. The company's cash runway appears limited to less than one quarter based on current burn rates, indicating an urgent need for additional capital or a significant reduction in spending. The high current ratio is driven by low current liabilities, not by ample cash.

Goodwill Impairment Could Erase Equity

Goodwill of $1.8B, per balance sheet data, is the largest asset and could be impaired if the company's market value falls, potentially wiping out a significant portion of the $2.5B equity.

The balance sheet's most non-obvious risk is the $1.8B goodwill balance, which represents 64% of total assets. If the company's market capitalization declines below its book value or if clinical or regulatory setbacks occur, an impairment charge could be triggered, reducing equity and potentially pushing the balance sheet into negative territory. Investors should monitor the company's market valuation relative to book value and any indicators of impairment, as this could have a material impact on the reported financial position.

GRAL — Frequently Asked Questions

Quick answers to the most common questions about buying GRAL stock.

What are the total assets of GRAIL Inc. (GRAL)?

As of 2025, GRAIL Inc. (GRAL) had total assets of $2.92B including $953.8M in current assets.

How much debt does GRAIL Inc. (GRAL) have?

GRAIL Inc. (GRAL) carries total debt of $98.0M, offset by $904.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of GRAIL Inc.?

GRAIL Inc. (GRAL) has total shareholders' equity (book value) of $2.58B ($70.14 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is GRAIL Inc.'s current ratio and liquidity?

GRAIL Inc. (GRAL) reported a current ratio of 11.97x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.